CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Ofatumumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01444716
NCT01444716Phase 2Completed
CompareCT.gov

Phase II Study of Ofatumumab as Front-Line Treatment in Elderly, Unfit Patients With Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center·interventional·Posted Oct 3, 2011·Updated Jul 26, 2021

In Brief

A Phase 2 clinical trial evaluating Ofatumumab for Chronic Lymphocytic Leukemia. Completed, enrolled 34 participants across 1 site.

Detailed Summary

This phase II trial studies how well ofatumumab works as front-line therapy in treating elderly participants with chronic lymphocytic leukemia. Monoclonal antibodies, such as ofatumumab, may interfere with the ability of cancer cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 3, 2011
Enrollment StartDec 15, 2011
Primary CompletionJun 11, 2020
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 14.7 years ago

Interventions

Ofatumumabbiological

Given IV